Association study of chemokine (C-C motif) ligand 5 gene polymorphism and papillary thyroid cancer

Journal of Investigative Surgery

Volumn 26, Issue 6, 2013, Pages 319-324

  Kwon, Kee Hwan ^a   Lee, Young Chan ^b   Chung, Joo Ho ^c   Eun, Young Gyu ^b  

^a Hallym University   (South Korea)

^b Kyung Hee University Hospital   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

CC chemokine ligand 5; Papillary thyroid cancer; Promoter; Single nucleotide polymorphism

Indexed keywords

CYSTEINE; RANTES; THREONINE;

ADULT; ANALYZER; ARTICLE; CANCER SIZE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CHEMOKINE CCL5; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; THYROID NEOPLASMS;

EID: 84887946277     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.3109/08941939.2013.805857     Document Type: Article

References (38)

1. Davies L,Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167
2. Goldgar DE, Easton DF, Cannon-Albright LA, et al. Systematic population-based assessment of cancer risk in firstdegree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600-1608
3. Czene K, Lichtenstein P, Hemminki K. Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer. 2002;99:260-266
4. Canzian F, Amati P, Harach HR, et al. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2. Am J Hum Genet. 1998;63:1743-1748
5. McKay JD, Lesueur F, Jonard L, et al. Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 2001;69:440-446
6. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow Lancet. 2001;357:539-545
7. Ben-Baruch A. The multifaceted roles of chemokines inmalignancy. Cancer Metastasis Rev. 2006;25:357-371
8. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol. 2004;14:149-154
9. Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer. 2006;42:768-778
10. Zlotnik A. Involvement of chemokine receptors in organspecific metastasis. Contrib Microbiol. 2006;13:191-199
11. Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53- dependent manner. J Exp Med. 2003;198:1381-1389
12. de la Rosa G, Longo N, Rodriguez-Fernandez JL, et al. Migration of human blood dendritic cells across endothelial cell monolayers: Adhesion molecules and chemokines involved in subset-specific transmigration. J Leukoc Biol. 2003;73:639-649
13. Roth SJ, Carr MW, Springer TA. C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-gamma inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes. Eur J Immunol. 1995;25:3482-3488
14. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990;347:669-671
15. Hizawa N, Yamaguchi E, Konno S, et al. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Respir Crit Care Med. 2002;166:686-690
16. Nakajima K, Tanaka Y, Nomiyama T, et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003;26:892- 898
17. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol. 2000;164:1612-1616
18. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A. 1999;96:4581-4585
19. McDermott DH, Beecroft MJ, Kleeberger CA, et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in theMulticenter AIDS Cohort Study. AIDS. 2000;14:2671-2678
20. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59:4681-4687
21. Niwa Y, Akamatsu H, Niwa H, et al. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285-289
22. Yaal-Hahoshen N, Shina S, Leider-Trejo L, et al. The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients. Clin Cancer Res. 2006;12:4474-4480
23. Saenz-Lopez P, Carretero R, Cozar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer. 2008;8:382
24. Weng CJ, Chien MH, Lin CW, et al. Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol. 2010;46:767-772
25. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol. 2001;2:108-115
26. Mashino K, Sadanaga N, Yamaguchi H, et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 2002;62:2937-2941
27. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56
28. Yasumoto K, Koizumi K, Kawashima A, et al. Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. Cancer Res. 2006;66:2181-2187
29. Gonzalez HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer. Thyroid. 2009;19:957-965
30. Kalinski P, Nakamura Y,Watchmaker P, et al. Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol Res. 2006;36:137-146
31. Tsukishiro S, Suzumori N, Nishikawa H, et al. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol. 2006;102:542-545
32. Vaday GG, Peehl DM, Kadam PA, et al. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate. 2006;66:124-134
33. Kondo T, Ito F, Nakazawa H, et al. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol. 2004;171:2171-2175
34. Moran CJ, Arenberg DA,Huang CC, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:3803-3812
35. Mule JJ, Custer M, Averbook B, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations.HumGene Ther. 1996;7:1545-1553
36. Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726-731
37. Bai B, Tanaka K, Tazawa T, et al. Association between RANTES promoter polymorphism -401A and enhanced RANTES production in atopic dermatitis patients. J Dermatol Sci. 2005;39:189-191
38. Liou JM, Lin JT, Huang SP, et al. RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol. 2008;43:115-123